Ed Shovelin on CRP-A Utilization in Diverse Research Areas
Ed Shovelin, Operations and Engineering Manager at Pplus Medical Limited, reposted from Pplus Medical Limited on LinkedIn:
”Its great to see the different research areas that scientists are utilizing CRP-A in.”
Quoting Pplus Medical Limited‘s post:
”CRP-A by Pplus Medical Limited is increasingly becoming a trusted platelet activator for leading researchers around the world, and we’re delighted to highlight the innovative work it helps make possible.
This week we want to share the following work by Professor Gawaz and his team at the Hospital of the university of Tübingen: Effect of phosphodiesterase inhibitors on platelet function.
Hypothesis: PDE2, PDE3 and PDE5 display differential effects on platelet-mediated thrombosis.
Methods: Compare the effects of PDE inhibition by Ibudilast, a non-selective inhibitor of several PDEs with preference towards PDE3, PDE4, PDE10 and PDE11, IBMX, a nonspecific PDE inhibitor and Sildenafil, a potent selective PDE5 inhibitor, respectively, on platelet activation, aggregation and thrombus formation.
How CRP-A was used: CRP-A was used to induce GPVI-mediated platelet activation, aggregation and thrombus formation.
Key Findings: Platelet activation by ADP via P2Y12 and TRAP6 via PAR1 showed a greater response to PDE inhibitors than platelet activation by CRP-A via GPVI”
Read the full article here.
Article: Effect of phosphodiesterase inhibitors on platelet function
Authors: Ravi Hochuli, Valerie Dicenta, Zoi Laspa, Manuel Sigle, Tobias Harm, Tatsiana Castor, Anne-Katrin Rohlfing, Meinrad Paul Gawaz
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 22, 2026, 15:36We Must Roll Up Our Sleeves And Help: José Antonio García Erce on Plasma Donation
-
Jan 22, 2026, 15:25Nita Radhakrishnan on Challenges In Congenital Afibrinogenemia
-
Jan 22, 2026, 15:10Jin Q Gives a Summary of 2025’s Most Impactful Cell and Gene Therapy Milestones
-
Jan 22, 2026, 14:57Nirav Dhanesha on CD14 Acting As A Functional Driver of DVT
-
Jan 22, 2026, 11:41Jamilla Goedegebuur and Colleagues on VTE Management in Case of PAD
-
Jan 22, 2026, 11:28Abdulrahman Katib on API-CAT Trial’s Evaluation of Apixaban Dosing
-
Jan 22, 2026, 11:19Bruno Odisio: Ablation Margins Are Software-Dependent
-
Jan 22, 2026, 10:38Pedro Perez: The VTE Market Is Clearly Entering Its Next Phase
-
Jan 22, 2026, 10:29Marvin Garcia Reyes Presents a Case of Aorto-Visceral and Aorto-Iliac Thrombosis